#CVCT2024 Workshop is on ! #clinicaltrials #clinicalresearch #futuretrialists – at Washington, DC

#CVCT2024: Studies using drugs approved for PAH in patients with PH associated with COPD have yielded conflicting results and are mostly limited by small sample size, short duration, and insufficient hemodynamic characterization of PH. In the absence of large randomized trials, the evidence is insufficient to support the general use of medication approved for PAH in patients with COPD and PH. In the recent ESC/ERS Guidelines, it is stated that patients with COPD and suspected or confirmed severe PH should be referred to PH centers for individual decision-making. A recently launched phase 3 RCT is testing an oral phosphodiesterase type 5 inhibitor (tadalafil) versus placebo (NCT05844462, ERASE PH-COPD) in severe PH associated with COPD. The ERASE PH-COPD will be the focus of this presentation. Join us December 9-11, Washington DC : globalcvctforum.com/scientif… @ValMcLaughlinMD @OSitbon @AlbertaPHdoc @HJFordMD #CVCT #clinicaltrials #clinicalresearch